Factor B-IN-8
Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3049710-19-9
- 分子式: C24H25F3N2O4
- 分子量:462.46
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | AUC0-t | AUC0-∞ | Vss | Tmax | F |
|---|---|---|---|---|---|---|---|---|---|
| Dog[1] | 3 mg/kg | i.v. | 3.16 h | 14947 ng/mL | 8333 ng·h/mL | 9487 ng·h/mL | 1.23 L/kg | / | / |
| Dog[1] | 6 mg/kg | i.g. | 5.83 h | 4680 ng/mL | 14388 ng·h/mL | 16738 ng·h/mL | / | 0.46 h | 86.77 % |
| Rat[1] | 10 mg/kg | i.v. | 10.58 h | 16788 ng/mL | 11413 ng·h/mL | 15313 ng·h/mL | 9.18 L/kg | / | / |
| Rat[1] | 20 mg/kg | i.g. | 9.28 h | 2659 ng/mL | 8793 ng·h/mL | 13505 ng·h/mL | / | 0.38 h | 51.82 % |
化学情報
-
CAS 番号 3049710-19-9
-
分子量 462.46
-
分子式 C24H25F3N2O4
-
SMILES
CC(C=C1OC)=C(NC=C2)C2=C1O[C@H]3[C@H](C4=CC=C(C=C4)C(O)=O)CN(CC3)CC(F)(F)F
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Factor B-IN-8 関連分類
HY-181040 関連分類
Powered by Bioz